KLK3 and metastatic prostate carcinoma: The current study included the metastatic prostate cancer patients treated only with PADT, also predicts the factor of progression to CRPC and showed a nadir PSA (<0.2 ng/mL vs. 0.2-4 ng/mL vs. ≥4 ng/mL) and the time from PADT to nadir (≥12 months vs. 6–12 months vs. <6 months) were independent factors for overall survival.